InterCure Ltd. (INCR)
USD 1.42
(-1.05%)
USD 1.42
(-1.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.9 Million ILS | -27.8% |
| 2022 | 64.5 Million ILS | 71.64% |
| 2021 | 37.44 Million ILS | 1981.94% |
| 2020 | -34.52 Million ILS | 108.51% |
| 2019 | -21.2 Million ILS | -159.82% |
| 2018 | -10.12 Million ILS | -647.8% |
| 2017 | -1.09 Million ILS | -2.06% |
| 2016 | - ILS | 34.78% |
| 2015 | -1.63 Million ILS | 25.74% |
| 2014 | -3.76 Million ILS | -17.4% |
| 2013 | -1.88 Million ILS | 11.53% |
| 2012 | 45.38 Million ILS | -28.99% |
| 2011 | -1.64 Million ILS | 64.16% |
| 2010 | -4.59 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.2 Million ILS | 256.74% |
| 2024 Q2 | 7.2 Million ILS | 0.0% |
| 2023 Q1 | 10.65 Million ILS | 275.01% |
| 2023 Q2 | 6.55 Million ILS | -38.47% |
| 2023 Q4 | -4.59 Million ILS | 3.68% |
| 2023 Q3 | -4.77 Million ILS | -172.78% |
| 2023 FY | - ILS | -27.8% |
| 2022 Q3 | 16.39 Million ILS | -38.82% |
| 2022 Q2 | 26.8 Million ILS | 19.7% |
| 2022 Q1 | 22.39 Million ILS | 65.57% |
| 2022 FY | - ILS | 71.64% |
| 2022 Q4 | -6.08 Million ILS | -137.12% |
| 2021 Q1 | 6.63 Million ILS | 21.9% |
| 2021 FY | - ILS | 1981.94% |
| 2021 Q4 | 13.52 Million ILS | 71.17% |
| 2021 Q2 | 9.51 Million ILS | 43.43% |
| 2021 Q3 | 7.9 Million ILS | -16.99% |
| 2020 Q3 | 4.35 Million ILS | 1030.77% |
| 2020 FY | - ILS | 108.51% |
| 2020 Q1 | -7.39 Million ILS | -123.47% |
| 2020 Q2 | -468 Thousand ILS | 93.67% |
| 2020 Q4 | 5.44 Million ILS | 24.98% |
| 2019 Q3 | -14.02 Million ILS | 4.23% |
| 2019 FY | - ILS | -159.82% |
| 2019 Q1 | 10.93 Million ILS | 321.45% |
| 2019 Q2 | -14.64 Million ILS | -233.93% |
| 2019 Q4 | -3.31 Million ILS | 76.4% |
| 2018 FY | - ILS | -647.8% |
| 2018 Q4 | -4.93 Million ILS | 0.0% |
| 2018 Q3 | -4.93 Million ILS | -3865.86% |
| 2018 Q2 | -124.5 Thousand ILS | 0.0% |
| 2018 Q1 | -124.5 Thousand ILS | 63.68% |
| 2017 Q4 | -342.82 Thousand ILS | 0.0% |
| 2017 Q3 | -342.82 Thousand ILS | -51.2% |
| 2017 Q1 | -235.42 Thousand ILS | 48.53% |
| 2017 Q2 | -226.73 Thousand ILS | 3.69% |
| 2017 FY | - ILS | -2.06% |
| 2016 Q2 | -289.19 Thousand ILS | -664.95% |
| 2016 Q1 | -37.8 Thousand ILS | 96.08% |
| 2016 FY | - ILS | 34.78% |
| 2016 Q4 | -457.37 Thousand ILS | -56.18% |
| 2016 Q3 | -292.84 Thousand ILS | -1.26% |
| 2015 FY | - ILS | 25.74% |
| 2015 Q3 | -369.33 Thousand ILS | -260.19% |
| 2015 Q2 | 230.56 Thousand ILS | 223.72% |
| 2015 Q1 | 71.22 Thousand ILS | 153.59% |
| 2015 Q4 | -963.72 Thousand ILS | -160.93% |
| 2014 Q3 | -427.52 Thousand ILS | 26.31% |
| 2014 Q2 | -580.13 Thousand ILS | -20.93% |
| 2014 Q1 | -479.74 Thousand ILS | -139.91% |
| 2014 FY | - ILS | -17.4% |
| 2014 Q4 | -132.89 Thousand ILS | 68.92% |
| 2013 Q4 | 1.2 Million ILS | 335.62% |
| 2013 FY | - ILS | 11.53% |
| 2013 Q3 | -510.22 Thousand ILS | 65.29% |
| 2013 Q2 | -1.47 Million ILS | -26.54% |
| 2013 Q1 | -1.16 Million ILS | 81.12% |
| 2012 Q1 | -274.89 Thousand ILS | -302.04% |
| 2012 Q2 | 2.39 Million ILS | 969.75% |
| 2012 Q3 | 1.91 Million ILS | -19.93% |
| 2012 Q4 | -6.15 Million ILS | -421.54% |
| 2012 FY | - ILS | -28.99% |
| 2011 FY | - ILS | 64.16% |
| 2011 Q3 | 136.06 Thousand ILS | 0.0% |
| 2011 Q1 | 136.06 Thousand ILS | 116.95% |
| 2011 Q2 | 136.06 Thousand ILS | 0.0% |
| 2011 Q4 | 136.06 Thousand ILS | 0.0% |
| 2010 Q4 | -802.73 Thousand ILS | 0.0% |
| 2010 Q1 | -802.73 Thousand ILS | 0.0% |
| 2010 Q3 | -802.73 Thousand ILS | 0.0% |
| 2010 FY | - ILS | 0.0% |
| 2010 Q2 | -802.73 Thousand ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -3262.172% |
| Harrow Health, Inc. | 9.72 Million USD | 345.809% |
| Dynavax Technologies Corporation | 9.66 Million USD | 347.258% |
| Biofrontera Inc. | -18.45 Million USD | -29.518% |
| DURECT Corporation | -24.68 Million USD | 3.176% |
| Cronos Group Inc. | -72.14 Million USD | 66.874% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.416% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 33.762% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 190.992% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -509.328% |
| Radius Health, Inc. | 38.31 Million USD | 162.386% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -643.374% |
| ProPhase Labs, Inc. | -14.82 Million USD | -61.192% |
| Phibro Animal Health Corporation | 84.6 Million USD | 128.248% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -916.584% |
| Procaps Group S.A. | 104.02 Million USD | 122.975% |
| Alvotech | -484.86 Million USD | 95.071% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -184.49% |
| Rockwell Medical, Inc. | -4.69 Million USD | -409.161% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -524.932% |
| Alpha Teknova, Inc. | -25.53 Million USD | 6.418% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 84.955% |
| SCYNEXIS, Inc. | 73.47 Million USD | 132.526% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -2261.66% |
| Theratechnologies Inc. | -10.31 Million USD | -131.751% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 121.862% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -428.177% |
| Safety Shot Inc | -12.18 Million USD | -96.14% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 124.323% |
| SIGA Technologies, Inc. | 84.15 Million USD | 128.398% |
| Tilray Brands, Inc. | -72.84 Million USD | 67.19% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 3043.35% |
| Viatris Inc. | 3.51 Billion USD | 100.68% |
| PetIQ, Inc. | 81.48 Million USD | 129.33% |
| OptiNose, Inc. | -15.55 Million USD | -53.668% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 105.744% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -524.932% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 166.332% |
| Alimera Sciences, Inc. | 7.27 Million USD | 428.477% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 107.751% |
| Silver Spike Investment Corp. | 7.34 Million USD | 425.608% |
| Assertio Holdings, Inc. | -222.44 Million USD | 89.256% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -498.9% |
| Cosmos Health Inc. | -17.06 Million USD | -40.079% |
| Journey Medical Corporation | 1.92 Million USD | 1344.144% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -467.444% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -42.228% |
| Embecta Corp. | 245.4 Million USD | 109.739% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -560.654% |
| Procaps Group, S.A. | 104.02 Million USD | 122.975% |
| PainReform Ltd. | -9.56 Million USD | -149.765% |
| Incannex Healthcare Limited | -18.5 Million USD | -29.161% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -19.316% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 83.973% |
| Shineco, Inc. | -26.55 Million USD | 9.994% |
| Talphera, Inc. | -9.84 Million USD | -142.837% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 114.672% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 2121.997% |
| Alvotech | -484.86 Million USD | 95.071% |
| Hempacco Co., Inc. | -12.77 Million USD | -87.11% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 130.838% |
| Lantheus Holdings, Inc. | 491 Million USD | 104.868% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 84.078% |
| Kamada Ltd. | 21.53 Million USD | 210.987% |
| Indivior PLC | 66 Million USD | 136.212% |
| Evoke Pharma, Inc. | -7.29 Million USD | -227.743% |
| Flora Growth Corp. | -45.87 Million USD | 47.896% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -19.316% |
| Evolus, Inc. | -41.81 Million USD | 42.837% |
| HUTCHMED (China) Limited | 25.52 Million USD | 193.623% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 109.898% |
| Akanda Corp. | -27.73 Million USD | 13.829% |